Indeed, high expression of PRDX4 and GSN might contribute to CRC and correlate with metastatic risk (p = 0.04 and p = 0.02; Figure 4, Table 3), as indicated by IHC assays in TMA. This evidence concerns the gene PRDX4 and colorectal carcinoma.